SCHEMBL5534005

SCHEMBL5534005

C#Cc1ccc(NC(=O)c2cc(Cl)cc(OC)c2NC(=O)c2ccc(N=CN3CCC(C(N)=O)CC3)cc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
F10 P00742 2/20 0.39
F2 P00734 1/20 0.38
LMNA P02545 1/20 0.36
MAPT P10636 4/20 0.36
HPGD P15428 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 7/20 0.36
KDM4E B2RXH2 3/20 0.36
TP53 P04637 1/20 0.36
KMT2A Q03164 2/20 0.36
GPR6 P46095 2/20 0.35
MEN1 O00255 1/20 0.35
KCNMA1 Q12791 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
KLK1 P06870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5528341 0.94 KCNH2 (0.44) KCNH2F10F2LMNAMAPT
SCHEMBL5532833 0.94 KCNH2 (0.42) KCNH2F10F2LMNAMAPT
SCHEMBL5528334 0.94 KCNH2 (0.44) KCNH2F10F2LMNAMAPT
SCHEMBL5532890 0.90 KCNH2 (0.53) KCNH2F10F2LMNAMAPT
SCHEMBL5532886 0.90 KCNH2 (0.53) KCNH2F10F2LMNAMAPT
SCHEMBL5536595 0.90 KCNH2 (0.39) KCNH2F10F2LMNAMAPT
SCHEMBL5534025 0.85 F10 (0.44) F10F2LMNAMAPTNPC1
SCHEMBL5533838 0.84 KCNH2 (0.51) KCNH2F10F2NPC1RAB9A
SCHEMBL5535298 0.84 F10 (0.41) KCNH2F10F2LMNAMAPT
SCHEMBL5531800 0.84 F10 (0.41) KCNH2F10F2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 KCNH2 1203/4885F10 10/4885F2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.